- Latest Headlines
- Kaleida Health Receives Strategic Integration Award
- Fastest Growing Private Frozen Yogurt Chain, Hoopla!, to Open in Orchard Park
- EPIC Donates Painting to Mother-Baby Unit at Women & Children’s Hospital of Buffalo
- Patient’s Fundraising Efforts Bring Music to Rooms at Women & Children’s Hospital of Buffalo
- Khalid Kakish, MD Appointed in Pediatric Neurology
- View All Headlines
- Kaleida in the News
- Media Advisories
- Press Releases
- Facts at a Glance
- KYI Newsletter
726 Exchange Street
Buffalo, NY 14210
DeGraff Memorial Hospital and Geriatric Center of WNY Receive IPRO Quality Award
IPRO is the Medicare Quality Improvement Organization (QIO) for New York State. The awards were given during IPRO’s 30th Annual Meeting in June.
“DeGraff Memorial Hospital and Geriatric Center of Western New York have demonstrated that a collaborative and focused effort, with management support, can lead to significant improvements in healthcare quality,” says Clare B. Bradley MD, MPH, senior vice president and chief medical officer, IPRO. “We thank all at this organization for their commitment to improving the health of New Yorkers.”
Their "Anticoagulation Management Program received the award for its exemplary performance in preventing oral anticoagulant adverse events. The organization was recognized for achieving a 75 percent average international normalized ratio (INR) time in therapeutic range for patients on warfarin. The service achieved a very low adverse drug event (ADE) rate of 1.3 percent and a rate of 9.2 percent of potential ADEs, outperforming national norms for both measures.
Anticoagulation therapy is designed to prevent life-threatening strokes and heart attacks, as well as to treat and prevent damaging or fatal blood clots. However, if not managed properly, it can lead to serious adverse events. The INR is a blood test that monitors whether the therapeutic or beneficial effect of warfarin is within normal range, a value usually between 2.0 and 3.0. Achievement of INR time in therapeutic range rates of greater than 70 percent is an indicator of a high quality anticoagulation management system that reduces blood clots and bleeding events in patients taking warfarin.
IPRO is a national organization providing a full spectrum of healthcare assessment and improvement services that foster more efficient use of resources and enhance healthcare quality to achieve better patient outcomes. For 30 years, IPRO has been highly regarded for the independence of its approach, the depth of its knowledge and experience, and the integrity of its programs. IPRO holds contracts with federal, state and local government agencies and corporate clients, in more than 33 states and the District of Columbia. A not-for-profit organization, IPRO is headquartered in Lake Success, NY. For more information about IPRO and a complete list of 2014 Quality Award winners, please visit www.ipro.org.